- $2.34bn
- $1.08bn
- $548.51m
HK's Hutchmed rises on progress of Orpathys Plus Tagrisso for cancer treatment
Brief: Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial
HUTCHMED Reports 2026 Interim Results
HUTCHMED climbs after China approves ORPATHYS for gastric cancer treatment
Brief: HUTCHMED (China) Announces NMPA Conditional Approval For Orpathys For Met-Amplified Advanced Gastric Cancer In China
HUTCHMED Announces NMPA Approval for ORPATHYS
Hutchmed To Announce 2026 Half: Year Results
HUTCHMED Highlights Phase II Data at ESMO
HUTCHMED Highlights Sovleplenib Phase III Data
AIM - AIM Notice - 11/06/2026
Block Admission Application
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals
HUTCHMED Highlights Data to be Presented at ASCO
NMPA approval for ELUNATE with TYVYT
Brief: Hutchmed (China) Announces NDA For Sovleplenib Accepted With Priority Review By NMPA
HUTCHMED Announces NDA Acceptance in China
2025 Annual Report and Notice of AGM
Data to be Presented at AACR Annual Meeting 2026
Hutchmed Initiates Phase Iii Trial Of Hmpl: 760